Euclidean Capital LLC: TENAYA THERAPEUTICS INC (TNYA): Quarterly 13F Position History
As of Q1 2026, Euclidean Capital LLC reported 1,015,705 shares of TENAYA THERAPEUTICS INC (TNYA), worth $703.3K and representing 0.2% of its 13F equity book. The position first appeared in Q3 2021 and has been disclosed across 19 13F-HR filings in Pactolio's tracked window.
- 1,015,705Shares Held (Latest Filing)
- $703.3KReported Market Value (Latest Filing)
- 0.2%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- -$19.4KQuarter-over-Quarter Value Change
- 1,015,705Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 19 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 1,015,705 | 0 | — | $703.3K | 0.2% | $0.7 |
| Q4 2025 | 1,015,705 | 0 | — | $722.7K | 0.2% | $0.7 |
| Q3 2025 | 1,015,705 | 0 | — | $1.6M | 0.7% | $1.6 |
| Q2 2025 | 1,015,705 | 0 | — | $620.8K | 0.2% | $0.6 |
| Q1 2025 | 1,015,705 | 0 | — | $579.1K | 0.2% | $0.6 |
| Q4 2024 | 1,015,705 | 0 | — | $1.5M | 0.2% | $1.4 |
| Q3 2024 | 1,015,705 | 0 | — | $2.0M | 0.2% | $1.9 |
| Q2 2024 | 1,015,705 | 0 | — | $3.1M | 0.4% | $3.1 |
| Q1 2024 | 1,015,705 | 0 | — | $5.3M | 0.7% | $5.2 |
| Q4 2023 | 1,015,705 | 0 | — | $3.3M | 0.4% | $3.2 |
| Q3 2023 | 1,015,705 | +100,000 | +10.9% | $2.6M | 0.6% | $2.5 |
| Q2 2023 | 915,705 | 0 | — | $5.4M | 1.4% | $5.9 |
| Q1 2023 | 915,705 | 0 | — | $2.6M | 2.3% | $2.9 |
| Q4 2022 | 915,705 | 0 | — | $1.8M | 1.7% | $2.0 |
| Q3 2022 | 915,705 | 0 | — | $2.7M | 2.5% | $2.9 |
| Q2 2022 | 915,705 | 0 | — | $5.2M | 4.4% | $5.6 |
| Q1 2022 | 915,705 | 0 | — | $10.8M | 6.3% | $11.8 |
| Q4 2021 | 915,705 | 0 | — | $17.4M | 9.9% | $19.0 |
| Q3 2021 | 915,705 | — | — | $18.9M | 9.2% | $20.6 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Euclidean Capital LLC first disclose a TNYA position in 13F-HR filings?
Euclidean Capital LLC first reported TENAYA THERAPEUTICS INC (TNYA) on its 13F-HR filing for the period ending 2021-09-30 (Q3 2021). The position has appeared on 19 reported quarters within Pactolio's tracked window.
What was Euclidean Capital LLC's most recent quarter-over-quarter share-count change in TNYA?
Euclidean Capital LLC held the same 1,015,705 shares of TNYA between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Euclidean Capital LLC's cost basis in TNYA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.